Interim report
Page 1
Vistin Pharma ASA – Third quarter report 2026 and YTD 2026 financial results Q3
Page 2
Vistin Pharma ASA – Third quarter report 2026 2 Highlights - Third quarter revenue of MNOK 108 with corresponding EBITDA of MNOK 19. Sales volume increased by 13% - N OK significantly stronger against EUR in third quarter of 2026 compared to 2025, affecting sales measured in NOK - MNOK 321 in revenue YTD 2026 compared to MNOK 342 YTD last year, a decrease of 6% - EBITDA of MNOK 19 positively affected by higher sales volume, offset by a weaker EUR. - EBI TDA YTD of MNOK 68 compared to MNOK 88 YTD 2025 - E PS for the first nine months of 2026 ended at NOK 1.05 compared to NOK 1.32 in the first nine months of 2025 - Sales volume from January to September 2026 of 4 710MT, an increase of 10% (+420 MT) compared to first nine months of 2025 - Ordinary cash dividend of total NOK 1 per share was paid out in the second quarter (MNOK ~44) - An additional ordinary cash dividend of NOK 0.5 per share to be paid in November - The main distillation vessel in production has reached the end of its normal lifespan and will need to be replaced. This is planned in an extended bi- annual maintenance stop in Q4 of four weeks where both lines will be idle. The planned stop will impact the production and sales volume correspondingly in the same quarter
Page 3
Vistin Pharma ASA – Third quarter report 2026 3 77 88 68 0 50 100 Q1-Q3 2024 Q1-Q3 2025 Q1-Q3 2026 EBITDA YTD Third quarter report for 2026 The financial report as per September 2026 has been prepared in accordance with IFRS (International Financial Reporting Standard) and follows IAS 34 for interim financial reporting, as do the comparable numbers for 2025. Financial development (Comparative numbers for 2025 in parenthesis). Revenue Revenue in the third quarter was MNOK 108.4 compared to MNOK 108.8 in Q3’25. The revenue decrease was driven by a lower average sales price (ASP) compared to same quarter last year as the spot price of Metformin fluctuates with the global raw material prices. FX neutral revenue in quarter increased by approximately 7%. Sales volume increased by 13%. YTD 2026 revenue was MNOK 321 compared to MNOK 342 YTD 2025, currency neutral revenue approximately flat. Sales volume YTD increased by 10% (+420 MT). Total operating expense (COGS) Total operating expense for the quarter ended at MNOK 89.5 (MNOK 80.8). The COGS increase compared to third quarter 2025 was mainly driven by increased volume (+13%). Raw material costs in the quarter are higher due to consumption of materials purchased in April/May when the Hormuz situation was on its most intense and drove up the prices. Salary costs are positively affected by no bonus accrual in Q3 2026, compared to an accrual of MNOK 2.5 in Q3 2025. Earnings EBITDA ended at MNOK 18.9 (MNOK 28) for the third quarter, which corresponds to a 17.4% margin. EBITDA was positively affected by higher sales volume, offset by stronger NOK vs EUR. Product mix and onboarding of customers in new regions also influenced the sales price. A stronger NOK compared to USD had a positive effect on raw material prices in the quarter. EBITDA YTD of MNOK 68 compared to MNOK 88 YTD 2025. 106 114 115 118 109 111 112 100 108 0 50 100 150 Revenues quarter 316 342 321 0 200 400 Q1-Q3 2024 Q1-Q3 2025 Q1-Q3 2026 Revenues YTD 29 28 30 30 28 26 27 22 19 0 5 10 15 20 25 30 35 EBITDA Quarter Figures in MNOK
Page 4
Vistin Pharma ASA – Third quarter report 2026 4 Production Production output in the third quarter was 1 550 MT Metformin. Production volume in the quarter was affected by some unplanned minor stops during the summer. Financial items Net finance was positive at MNOK 0.1 for the third quarter of 2026, compared to positive net finance of MNOK 2.4 in the same quarter of 2025. Finance income and loss are in general related to realized and unrealized FX losses from customers receivables, currency hedging contracts in EUR and interest expense from credit overdraft. Finance income in Q3 2026 was mainly related to realized gain from FX hedging contracts for 2026, offset by FX loss on accounts receivables due to strengthening of NOK during the quarter. Cash flow Net cash flow for first nine months of 2026 from operating activities was positive with MNOK 62.2. Net cash flow from operating activities in the same period of 2025 was positive with MNOK 37.2. Net cash flow from investing activities YTD 2026 was negative with MNOK 10.7. This amount was constituted mainly by capital expenditure. Net cash flow from investing activities in the same period last year was negative with MNOK 10.2 also mainly representing capital expenditure. Net cash flow from financing activities YTD 2026 was negative with MNOK 45.9. Net cash flow from financing activities YTD 2025 was negative with MNOK 36.4. For both periods, the main driver in financing activities was dividend payment of MNOK 44.4 in 2026 and MNOK 55.4 in 2025, in latter partly offset by utilizing the bank overdraft. Net change in cash and cash equivalents in the first nine months of 2026 was positive with MNOK 5.6. In the same period last year, there was a net decrease in cash equivalents of MNOK 9.4 Balance sheet Assets Vistin Pharma had total assets of MNOK 421.7 as of 30 September 2026 (MNOK 425.1). Equity Equity by the end of September was MNOK 331 (MNOK 312.8). This equals an equity ratio of 78% (74%). Equity ratio is calculated as dividing its total shareholder equity to its total assets. Liabilities Cash position at quarter end of MNOK 22 with no interest-bearing bank loans, compared to net debt of MNOK 18.6 as of end September 2025. MNOK 0.6 (MNOK 1.7) in obligations r elated to lease contracts are recognized in the balance sheet according to IFRS 16. 1500 1470 1350 1480 1600 1 460 1440 1560 1550 0 200 400 600 800 1000 1200 1400 1600 1800 Production volume metformin in metric tons
Page 5
Vistin Pharma ASA – Third quarter report 2026 5 Operational status Market Diabetes is one of the most serious diseases of this century. The number of diabetes patients are expected by WHO to grow from approximately 590 million patients today to more than 850 million within 25 years. About 11% of the world’s population in the age group between 25 – 79 years are living with diabetes. The global demand for Metformin API is expected to grow by approximately 31.000MT to 109.000MT (metric tons) by 2030. Metformin is the standard first-line treatment of Type II Diabetes, which represents around 90% of the global diabetes cases. Vistin Pharma’s key customers are leading pharmaceutical companies that use our API into innovative and generic Metformin drug products to the end market. The product demand will therefore be dependent on the performance of these products in the market. Key drivers for future growth are the number of diabetes patients diagnosed and treated with Metformin-containing products, continued growth in sales volume from existing international customers, as well as adding new customers to Vistin’s portfolio. The company is currently experiencing good demand for its products. Strategy Vistin’s strategy is to build a >7000 MT Metformin business through world class operations and strategic customer partnerships in order to maintain and over time grow the global market share. Further, it is our ambition to make our manufacturing site the most technologically advanced and environmentally sustainable state-of-the-art Metformin plant in the world. Vistin has positioned itself as a premium supplier in the highly competitive Metformin market, and to become a front runner on sustainability by continuous focus and inn ovation on reduction of emissions and waste production. Vistin is one of two European Metformin manufacturers, and the only one with a dedicated facility. Vistin Pharma believes that the quality of its Metformin products, its advanced, fully automated production facility, continuous focus on and investment in sustainable operations, and its service and delivery performance, are competitive advantages and drivers for increased sales and future growth. After installation of the new second production line (MEP) in 2022, the company has been focusing on ramping up volume from the two production lines. A significant part of the company’s resources engages in optimizing output and building efficient and robust processes to achieve up to 7000MT of annual Metformin HCl output, and sales volume accordingly. Higher manufacturing and sales volumes going forward are expected to increase working capital requirements, however this will fluctuate from quarter to quarter. In addition, Vistin’s further growth ambitions will require some additional CAPEX to support growth, increased productivity, and sustainability. Vistin has a strategy of keeping additional safety stock of critical raw materials and finished goods to secure future supply and support the ramp-up plan. Such safety stock is planned to mitigate potential irregularities or delays in delivery lead times of raw material from Asia and/or any negative effects from the ongoing wars in the Middle East and Ukraine. Vistin may also hold certain levels of safety stock for its tier-one customers. Vistin Pharma’s long-term vision is to have no negative impact on the environment, people, and local community by the Company’s presence. Vistin Pharma is proud of the sustainability achievements, the track record of deliverables and ongoing ESG focus and investments to further reduce the Company’s
Page 6
Vistin Pharma ASA – Third quarter report 2026 6 c arbon footprint. Vistin Pharma’s customers are, to a growing extent, also requesting and expecting their suppliers to support the shift towards a sustainable future. Vistin is strategically well positioned to fulfil these needs being situated in Norway with renewable hydropower and stable environmental focus. Sales & Marketing Our Metformin strategy is to grow with our existing and new customers, fulfilling their demands and gradually utilize all available production capacity by increasing our market share via active sales Business to Business (B2B). V istin has a global footprint and exports 100% of our product globally all the way from Far East to Latin America. Vistin API is registered and used in more than 100 countries today. Our main sales model is direct sales, but we also work with distributors and agents. R ecently we have been increasing our sales activities into new regions and countries in Asia and the Middle East, two regions where the growth of diabetes 2 and the medical need is high. O ur Metformin distinguishes itself from competitors by being more easily processable (saves manufacturing time), contains less residual DMA and no nitrosamines. In addition, Vistin has an exceptionally low carbon footprint due to the use of 100% renewable hydropower in the high energy consuming manufacturing of Metformin, rather than using coal power which is used in Asia. Competitive drugs New diabetes drugs will always enter the market being effective in separate ways. This was the case with the DDP4 and SGLT2 combination products in past years, and now also with the GLP-1 diabetes type 2 treatment with weight reducing effect. However, Metformin is used as baseline treatment, and the combination drugs are typically added on top of Metformin. Because Metformin is a safe, efficacious drug product with a monthly treatment cost of as low as 4-5 USD, it is an easy treatment choice for prescribing doctors and an obvious choice for low-and middle- income countries where drugs are paid out-of- pocket. Research and Development (R&D) Vistin is positioned as a premium supplier in the market. To strengthen this position, Vistin is committed to invest in process and product quality development and take advantage of Best Available Techniques (BAT) in its production environment. Vistin has a separate department consisting of four highly competent engineers dedicated to work with process, productivity, and quality improvements. Strategic intent There are advantages being a dedicated Metformin supplier because we can allocate all our focus and flexibility to our customers. However, we are in a strategic process looking into options for further strengthening our business outside of the Metformin landscape. We have previously communicated to the market that we have a strategic intent to grow further and increase the number of products within our portfolio. Growth may come from M&A activity, establishing a European multiproduct Contract Development and Manufacturing Organization (CDMO) and/or expanding our capacity even further within the Metformin space. V istin Pharma owns 15% of CF Pharma. CF Pharma is an API CDMO located in Budapest, Hungary and has an extensive production site in Budapest, with an experienced R&D department for development of new products and processes. The company has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs).
Page 7
Vistin Pharma ASA – Third quarter report 2026 7
Page 8
Vistin Pharma ASA – Third quarter report 2026 8
Page 9
Vistin Pharma ASA – Third quarter report 2026 9
Page 10
Vistin Pharma ASA – Third quarter report 2026 10
Page 11
Vistin Pharma ASA – Third quarter report 2026 11
Page 12
Vistin Pharma ASA – Third quarter report 2026 12 Corporate social responsibility, the environment and employees Vistin Pharma aspires to achieve sustainable development by having a good balance between financial results, value creation, sustainability, and CSR. The Board of Directors have the overall responsibility for aligning Vistin’s strategy and sustainability considerations, while the day-to-day responsibility lies with the CEO, supported by the Leadership Team. The statement of corporate social responsibility required under the Norwegian Accounting Act was published in June on the Company’s website. Vistin Pharma is committed to conduct its business in a manner that adheres to the highest industry standards within the pharmaceutical industry, and strictly in accordance with international and local laws and regulations. Vistin Pharma is a socially responsible company dedicated to promoting decent working and environmental conditions in the supply chains. Vistin Pharma has adopted the general principles of UN Global Compact with universally accepted principles for human rights, working conditions, environment, and anti-corruption. In pursuit of this the Company has developed a ‘NO HARM VISION’. Risks and uncertainties As a pharmaceutical manufacturing company, Vistin Pharma is exposed to several types of risk. Fluctuations in the price and availability of raw materials and the development in foreign exchange (USD and EUR) are among the most prominent. The majority of sales are denominated in EUR, while all primary raw material purchases are in USD. In addition, risk related to potential regulatory changes, new medications for the treatment of diabetes II, and environmental issues connected to emission permits at the Company’s plant, represent central risk factors to the Company. Vistin has currently not experienced any changes in demand or behaviour from customers in relation to the ongoing US tariff discussions. Direct sales to USA are less than 5% of Vistin’s total sales. General market outlook Diabetes is one of the largest global health crises of the 21st century, and the demand for Metformin medication is expected to continue to grow by 4-6% annually, as it remains the standard baseline treatment for type 2 diabetes. The demand for Metformin in the market is generally stable also considering the current political landscape. Vistin is strategically well positioned to benefit from the expected stronger demand for local supplies from Europe going forward. GLP-1 agonists have recently become quite popular in high income countries to treat obesity and diabetes type 2. It is quite common to use for example the GLP-1 agonist Semaglutide in combination with metformin for managing type 2 diabetes. This combination is often prescribed because the two medications complement each other in controlling blood sugar levels. Semaglutide helps by stimulating insulin secretion, suppressing glucagon release, slowing digestion, and reducing liver glucose production. Metformin primarily works by decreasing glucose production in the liver and improving insulin sensitivity.
Page 13
Vistin Pharma ASA – Third quarter report 2026 13 Long and successful growth track record 88 101 111 142 150 176 171 177 201 228 254 279 305 438 430 452 0 50 100 150 200 250 300 350 400 450 500 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Revenues Vistin metformin (MNOK)
Page 14
Vistin Pharma ASA – Third quarter report 2026 14 IFRS 18 – Presentation and Disclosure in Financial Statements IFRS 18 replaces IAS 1 for annual reporting periods beginning on or after 1 January 2027 and introduces new requirements for the presentation and disclosure of financial performance, including defined categories and subtotals in the statement of profit or loss and disclosures relating to management-defined performance measures. Vistin Pharma is assessing the impact of the new standard and preparing for implementation. As part of this assessment, the Company is evaluating the classification of foreign exchange differences related to trade receivables and gains and losses on currency contracts, which are currently presented within financial income and expenses. Depending on their nature and the applicable requirements of IFRS 18, certain items may be presented within the operating category, which could affect reported operating profit and operating margins. The potential effect on EBITDA will also depend on how the measure is defined and presented under the new reporting framework. The assessment also includes the new disclosure requirements for management- defined performance measures and any consequential changes to the presentation of the statement of cash flows. Changes in presentation and classification will not, in themselves, affect profit for the period or total equity. IFRS 18 will be applied retrospectively, and comparative information for 2026 will therefore be restated when the standard is first applied. Basi s of presentation This financial information should be read together with the financial statements for the year ended 31 December 2025, prepared in accordance with International Financial Reporting Standards (“IFRS”). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Additional disclosures supplementing the financial statements are included in this report on pages 2–5. The figures are unaudited. Shareholder information The Company had 44 344 592 issued shares as of 30 September 2026. The five largest shareholders were Intertrade Shipping AS with 14,509,280 shares, Holmen Spesialfond with 4,371,558 shares, Pactum Vekst AS with 2,991,773 shares, MP Pensjon PK with 1,719,848 shares, and Surfside Holding AS with 1,552,960 shares. The share price has moved from NOK 20.60 per share as of 30 June 2026, to NOK 18.50 as of 30 September 2026. Dividend policy The company aims to distribute 50% of annual net profit as dividends. However, the size of the dividend will be dependent on the company’s financial capability and capital requirements for future growth. An ordinary cash dividend of total NOK 1 per share was paid out in June. Additional ordinary cash dividend of NOK 0.5 to be paid in November, according to the power of attorney received from the Annual General Meeting on the 20th of May 2026. Events after the reporting date There have not been events after the reporting date that affect the Company’s financials.
Page 15
Vistin Pharma ASA – Third quarter report 2026 15 25 -5 46 63 75 -10 0 10 20 30 40 50 60 70 80 2021 2022 2023 2024 2025 +202% Earnings per share 2021-25 Net Profit 2021-25 (MNOK) APM - Alternative Performance Measure The Company presents certain financial reconciliations and performance measures in this quarterly report that are not defined under IFRS. These are referred to as Alternative Performance Measures. We believe currency neutral revenue is valuable additional information for assessing and understanding the Company’s underlying operating performance, profitability and financial development over time. Currency-neutral revenue is calculated by comparing the current year’s revenue with the corresponding period in the previous year, recalculating current -year revenue denominated in foreign currencies using the average exchange rates applicable to the corresponding prior-year period. Reconciliation of currency neutral revenue Rates Q3 2026 Rates Q3 2025 Rates Q1-Q3 2026 Rates Q1-Q3 2025 EUR average rate for the year 10,93 11,79 11,08 11,7 USD average rate for the year 9,51 10,10 9,55 10,5 Sp lit of revenue in EUR and USD Rev enue Q3 2026 Rev enue Q3 2026 with 2025 rates Rev enue Q1-Q3 2026 Rev enue Q1- Q3 2026 with 2025 rates EUR revenue in MNOK 88,9 95,9 257,4 271,8 USD revenue in MNOK 19,5 20,7 63,4 69,7 0,56 -0,11 1,03 1,42 1,69 -0,20 0,00 0,20 0,40 0,60 0,80 1,00 1,20 1,40 1,60 1,80 2021 2022 2023 2024 2025 +202%
Page 16
Vistin Pharma ASA – Third quarter report 2026 16 Condensed financial statement (P&L) Q3 2026 Q3 2025 YTD 2026 YTD 2025 FY 2025 All numbers in NOK 1000 Total revenue 108 391 108 840 320 808 341 546 452 291 Cost of materials 43 645 31 515 113 985 113 433 151 507 Salary and social expenses 23 824 27 140 70 577 74 666 98 516 Other operating expenses 22 071 22 139 68 012 64 911 87 383 Total operating expenses 89 540 80 793 252 574 253 010 337 406 Operating result before depr. (EBITDA) 18 852 28 047 68 234 88 536 114 885 Operating result before depr. % 17 % 26 % 21 % 26 % 25 % Depreciation 5 879 6 703 17 687 17 000 22 532 Operating result (EBIT) 12 972 21 344 50 547 71 536 92 354 Operating result in % 12 % 20 % 16 % 21 % 20 % Financial income 3 290 4 757 20 966 13 036 14 502 Financial expenses 3 220 2 351 12 793 9 323 11 017 Net finance 70 2 405 8 173 3 713 3 485 Pre-tax profit (EBT) 13 042 23 750 58 720 75 249 95 839 Tax 2 097 5 225 12 146 16 555 21 089 Result 10 946 18 525 46 574 58 694 74 751 Comprehensive income Result after tax 10 946 18 525 46 574 58 694 74 751 Other comprehensive income - - - - -36 Total comprehensive income 10 946 18 525 46 574 58 694 74 716 Key figures Q3 2026 Q3 2025 YTD 2026 YTD 2025 FY 2025 Equity share 78 % 74 % 78 % 74 % 75 % Earnings per share 0,25 0,42 1,05 1,32 1,69 Average shares outstanding in 1000 44 345 44 345 44 345 44 345 44 345
Page 17
Vistin Pharma ASA – Third quarter report 2026 17 Condensed financial statement (balance sheet) 30.09.2026 30.09.2025 31.12.2025 All numbers in NOK 1000 Assets Fixed assets 216 804 222 776 223 754 Financial assets 12 154 12 154 12 154 Total non-current assets 228 959 234 931 235 909 Inventory 70 485 91 388 82 133 Trade receivables 84 261 85 344 89 712 Other receivables 15 987 10 007 15 259 Cash 22 043 3 395 16 419 Total current assets 192 775 190 135 203 524 Total assets 421 735 425 066 439 432 Equity and liability Share capital 44 345 44 345 44 345 Share premium reserve 29 522 73 867 73 867 Retained earnings 257 176 194 583 210 602 Total equity 331 044 312 795 328 814 Pension liabilities 6 094 6 279 6 415 Deferred tax liabilities 29 782 20 073 16 862 Other non-current liabilities 27 827 619 Total long-term liabilities 35 903 27 179 23 896 Trade payables 18 146 19 677 30 238 Short term debt - 21 022 - Tax payable - - 7 734 Other current liabilities 36 642 44 393 48 748 Total short-term liabilities 54 787 85 092 86 720 Total equity and liabilities 421 735 425 066 439 432
Page 18
Vistin Pharma ASA – Third quarter report 2026 18 Change in equity 30.09.2026 30.09.2025 31.12.2025 All numbers in NOK 1000 Equity starts of period 328 814 309 529 309 529 Result for the period 46 574 58 694 74 751 Other comprehensive income - - -36 Dividend -44 345 -55 431 -55 431 Equity end of period 331 044 312 795 328 814 Cash flow analysis YTD 30.09.2026 30.09.2025 31.12.2025 All numbers in NOK 1000 Profit Before Tax (EBT) 58 720 75 249 95 839 Depreciations 17 687 17 000 22 532 Income tax paid -6 961 - - Working capital changes -7 217 -55 027 -40 335 Cash flow from operation 62 228 37 223 78 036 Purchase of equipment -10 737 -10 174 -16 288 Cash flow from investments -10 737 -10 174 -16 288 Dividend paid -44 345 -55 431 -55 431 Repayment of lease liabilities -791 -752 -884 Interest paid -733 -1 286 - 1 810 Short term debt 21 022 Cash flow finance activities -45 868 -36 447 -58 125 Change in cash for the period 5 624 -9 399 3 624 Cash at start of period 16 419 12 795 12 796 Cash by the end of period 22 043 3 395 16 419
Page 19
Vistin Pharma ASA – Third quarter report 2026 19 Vistin Pharma ASA Østensjøveien 27 NO-0661 Oslo Norway Tel: +47 35 98 42 00 E-mail: vistin@vistin.com www.vistin.com